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Abstract Transsphenoidal surgery (TSS) is first-line
treatment for Cushing’s disease (CD), a devastating dis-
order of hypercortisolism resulting from overproduction of
adrenocorticotropic hormone by a pituitary adenoma.
Surgical success rates vary widely and disease may recur
years after remission is achieved. Recognizing CD recur-
rence can be challenging; although there is general
acceptance among endocrinologists that patients need
lifelong follow-up, there are currently no standardized
monitoring guidelines. To begin addressing this need we
created a novel, systematic algorithm by integrating
information from literature on relapse rates in surgically-
treated CD patients and our own clinical experiences.
Reported recurrence rates range from 3 to 47 % (mean time
to recurrence 16–49 months), emphasizing the need for
careful post-surgical patient monitoring. We recommend
that patients with post-operative serum cortisol \2 lg/dL
(measured 2–3 days post-surgery) be monitored semian-
nually for 3 years and annually thereafter. Patients with
post-operative cortisol between 2 and 5 lg/dL may expe-
rience persistent or subclinical CD and should be evaluated
every 2–3 months until biochemical control is achieved or
additional treatment is initiated. Post-operative cortisol
[5 lg/dL often signifies persistent disease and second-line
treatment (e.g., immediate repeat pituitary surgery, radio-
therapy, and/or medical therapy) may be considered. This
follow-up algorithm aims to (a) enable early diagnosis and
treatment of recurrent CD, thereby minimizing the detri-
mental effects of hypercortisolism, and (b) begin
addressing the need for standardized guidelines for vigilant
monitoring of CD patients treated by TSS, as demonstrated
by the reported rates of recurrence.
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Introduction
Cushing’s disease (CD), a rare illness characterized by
chronic hypercortisolemia secondary to the overproduction
of adrenocorticotropic hormone (ACTH) by a pituitary
adenoma, is associated with high risk of developing serious
complications such as diabetes mellitus, cardiovascular
disease, and depression, and a mortality rate between 1.7-
and 4.8-fold higher than that of the general population [1].
The primary treatment of choice for CD is adenomec-
tomy by transsphenoidal surgery (TSS). Surgical success
rates are variable, ranging from 65 to 90 %, and depend on
surgeon expertise [2, 3]. Furthermore, criteria and testing
parameters for assessing immediate remission vary from
center to center, making the interpretation of results chal-
lenging [4, 5]. Additionally, post-surgical recurrence of CD
is not uncommon, with reported recurrence rates ranging
from 3 to 47 % [6, 7], and an observed mean time to
recurrence of 16–49 months [3]. For patients in whom
pituitary surgery fails or is contraindicated, radiotherapy or
medical treatment are alternative options.
Given the complications associated with untreated CD,
it is crucial that patients receive appropriate post-surgical
follow-up so that recurrence is identified and treated as
early as possible. However, despite this urgency there is
little published information on systematic post-surgical
patient monitoring and no standardized guidelines for
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follow-up evaluation have been established. Moreover,
patients may ultimately seek care in a wide variety of
primary care and specialist settings, particularly as remis-
sion time increases, thereby necessitating a wider under-
standing of CD sequelae and the importance of lifelong
monitoring to detect any early signs of recurrence across
multiple disciplines. The aims of this review are to provide
a critical overview of reported short- and long-term out-
comes following surgical treatment of CD, and to propose a
practical algorithm for monitoring post-surgical patients in
order to detect and treat recurrence swiftly.
Defining surgical success
The criteria for determining immediate remission follow-
ing surgery are not standardized and vary widely across
centers. Variability occurs in the types of biochemical
parameters used to evaluate success, the assays used, lim-
itations of the assays, and the timing of measurements [8].
Furthermore, results can be confounded by other factors,
such as peri-operative administration of glucocorticoids
and pre-operative treatment with steroidogenesis inhibitors
[4, 5].
Biochemical indication of remission
Early morning serum cortisol measured between 8 and 10
a.m. is the most commonly utilized measure of immediate
remission following surgery. Cortisol secretion normally
follows a diurnal pattern with highest levels between 7–9
a.m. that decline to lowest levels around 10–11 p.m. [9]. In
patients with CD, the circadian rhythm is aberrant and
cortisol levels remain consistently elevated [9, 10]. The
goals of pituitary surgery are to extract the ACTH-secret-
ing adenoma and subsequently reduce cortisol levels,
leading to improvements in the signs and symptoms of CD.
Surgical success is confirmed by subnormal levels of
early morning serum cortisol measured within a few days
of surgery. Typically, early morning serum cortisol levels
of either \2 lg/dL (*50 nmol/L) or \5 lg/dL within a
few days after surgery are considered to be indicative of
remission [3]. However, reported results are mixed and
difficult to interpret since some studies measure basal
serum cortisol levels while others use serum cortisol fol-
lowing dexamethasone suppression, or some combination
of these measures [5, 11–13]. While clinical practice
guidelines provide recommendations for testing in the
context of initial diagnosis of CD [10], there is no expert
consensus with regard to post-operative testing for surgical
success.
The timing of biochemical measurements differs among
treatment centers and can vary considerably within the
same center. Intervals between surgery and biochemical
measurement range from 1 to 2 days [14, 15], up to several
weeks [16, 17], and even months [14]. As a result, the
definition of post-surgical remission is unclear.
Other confounding factors
This is further complicated by the fact that several cir-
cumstances can influence serum cortisol levels. Prophy-
lactic medical treatments are often used prior to or during
surgery to control cortisol levels in patients with CD. Since
successful pituitary adenomectomy typically results in
adrenal insufficiency, glucocorticoids are commonly
administered peri- and/or pre-operatively [5]. On the other
hand, because invasive surgery is a stressful procedure that
elevates cortisol levels [18, 19], some centers attempt to
mitigate such elevations in patients with CD, who are
already hypercortisolemic as a result of the disease, prior to
TSS [3, 20]. Steroidogenesis inhibitors, such as ketocona-
zole and metyrapone, may be administered for several
weeks preceding adenomectomy [12, 21]. While the prac-
tice considers the patient’s best interest, pre-operative
administration of these drugs often delays surgery and can
pose challenges to the evaluation of remission status
immediately following surgery. It is possible that adrenal
insufficiency might be exaggerated by the action of these
drugs and potentially falsely identifies some cases as sur-
gical successes. It is therefore important for clinicians to
time preoperative treatment discontinuation in order to
avoid mistaking remission.
Predicting recurrence
There are conflicting data relating to whether it is possible
to identify patients who may be at greater risk for recur-
rence of CD following pituitary surgery. For instance, there
is some evidence that tumor size, age, and gender may
predict long-term outcome following surgery, and that the
likelihood of recurrence may be higher in patients with
macroadenomas [22–25], and patients who are younger
[26]. However, a thorough review and meta-analysis of
various predictive factors of recurrence found that age,
gender, tumor size, and macroscopic tumor invasion were
not associated with CD recurrence, whereas low levels of
cortisol immediately following surgery appeared to be a
positive predictor of long-term remission in more reports
than not [27]. Therefore, it is unclear to what extent
recurrence can be predicted, highlighting the importance of
regular post-surgical patient monitoring.
Whether consideration of post-surgical adrenal insuffi-
ciency in conjunction with other parameters predicts
recurrence better than post-surgical cortisol levels alone is
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also unclear. In one study, recovery from transient post-
surgical adrenal insufficiency (2–34 months) followed by
normalized hypothalamus–pituitary–adrenal (HPA) axis
function predicted a low recurrence rate (13 %), whereas
lack of a diurnal rhythm of cortisol secretion after nor-
malized adrenal function predicted significantly higher
recurrence rates (50–65 %) [28]. In contrast, results from
another study showed that the time to complete normali-
zation of the HPA axis following surgery was the only
positive indicator of recurrence; all patients who recurred
had recovered their HPA axis function within 3 years of
surgery [29]. Yet others report that a lower risk of recur-
rence was associated with normal cortisol suppression by
low-dose dexamethasone [30, 31]. Similarly, high levels of
ACTH in response to corticotrophin-releasing hormone
(CRH) or desmopressin stimulation better predicted relapse
than post-operative serum cortisol levels alone [32–36]. As
such, it is plausible that patients with subtle abnormalities
of the HPA axis following surgery may be at risk for
persistent or recurrent hypercortisolemia, which may be
mild yet insidious.
Subclinical CD: a conundrum
Hypercortisolemia resultant from an aberrant HPA axis can
be mild, which leads to challenges with appropriately
diagnosing the patient. As in most cases of subtle disease,
definition of ‘subclinical’ Cushing’s syndrome (SCS), or
endogenous hypercortisolemia, is somewhat ambiguous,
controversial, and ill-defined. The term, almost invariably
related to adrenocortical tumors, is used to describe mild
hypercortisolism in the absence of the cardinal features
such as violaceous striae and proximal myopathy that are
commonly observed in overt Cushing’s syndrome.
Surprisingly, SCS is not a term used to call attention to
the subtle hypercortisolemia commonly observed following
adenomectomy for CD. Furthermore, to the best of our
knowledge, there are no controlled studies focusing on the
consequences of subtle or intermittent hypercortisolism in
patients who have undergone surgery. This knowledge gap
may, in part, be as a result of difficulties inherent to the
diagnosis of mild forms of CD in the early post-operative
period. Similarly, the lack of a standardized approach to
evaluate the HPA axis in patients with CD following sur-
gery may be partially due to the inconsistency and unreli-
ability of diagnostic tests under different circumstances or
severity of disease. This phenomenon, or spectrum effect,
is used to emphasize this concept in which the sensitivity
and specificity of tests are not fixed, but rather vary with
the severity or temporal state of the disease being consid-
ered [37].
Somatic consequences of mild hypercortisolemia may
be subtle or subclinical, but over time will be additive and
inexorable. Evidence implies that patients may develop
complications associated with long-term exposure to hy-
percortisolemia, such as diabetes mellitus, metabolic dis-
turbances, and obesity [38]. More importantly, patients
with SCS caused by hormonally active adrenal tumors may
exhibit slow, long-term progression of these symptoms if
not surgically treated. A retrospective study involving[100
patients suggested that treating SCS by means of laparo-
scopic adrenalectomy may improve blood pressure control,
weight control, and carbohydrate metabolism [39].
In summary, persistent, subtle, autonomous ACTH
secretion that engenders mild, yet continually elevated
levels of cortisol is difficult to diagnose due to the presence
of interfering clinical conditions, such as obesity and
depression, which are more prevalent in the general pop-
ulation, and heterogeneity in severity or temporal stage of
the disease among subgroups of examined patients. This
problem can be mitigated by developing a structured and
standardized approach to the evaluation of patients who
undergo pituitary surgery for CD.
Post-surgical patient monitoring
As discussed, there is no single parameter that assures
permanent cure of CD. As such, a meticulous post-surgical
monitoring regimen is the best approach to timely detection
of recurrence. However, to date, follow-up protocols have
only been reported in a handful of studies and differ from
center to center [13, 15, 28]. In general, the most frequent
follow-ups are done within the first year following pituitary
surgery, after which monitoring frequency typically tapers
off to once a year. Benefits to this follow-up protocol are
that any cases of delayed remission can be identified and
cases of hypocortisolism or hypopituitarism that may result
from damage to the pituitary during surgery can be dis-
covered early and treated. However, incidence of recur-
rence peaks within 1–5 years post-surgery with sizeable
incidence also reported between 5 and 10 years of follow-
up [27]. This emphasizes the need for a vigilant and uni-
form monitoring protocol to capture any early biochemical
signs of recurrence.
Proposed algorithm for patient follow-up
As demonstrated, there is a lack of standardized post-sur-
gical monitoring of patients with CD. To address this gap
in clinical practice, we propose an evidence- and empiri-
cally-based algorithm to facilitate early detection and
treatment of recurrence (Fig. 1). As determined by post-
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Fig. 1 Proposed algorithm for the post-operative monitoring of
patients with CD. Evaluation strategies are determined by a patient’s
immediate post-surgical status as determined by early morning serum
cortisol levels. Asterisk repeat surgery practice varies by center.
Longer follow-up could be considered in patients with subnormal
levels of post-operative cortisol as they may either experience delayed
remission and/or may not necessarily experience recurrence. Re-
intervention can be considered if cortisol levels begin to rise or if
symptoms of the disease return. Dagger UFC upper limit of normal
(ULN) as determined by specific assay used. Double dagger medical
therapy: pasireotide (somatostatin analog), cabergoline (dopamine
receptor agonists), mifepristone (glucocorticoid receptor antagonist),
steroidogenesis inhibitors (ketoconazole, mitotane, etomidate,
metyrapone)
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surgical early morning (8–10 a.m.) serum cortisol levels
measured 2–3 days post-surgery, patients may be catego-
rized as being in immediate remission (cortisol \2 lg/dL)
[40, 41], potentially persistent (cortisol 2–5 lg/dL), or
persistent (i.e., surgical failures; cortisol [5 lg/dL). Dif-
ferent courses of action are suggested for each of the three
outcomes. As there is a scarcity of timing guidelines in the
literature, proposed timing of evaluations is based on our
own experiences.
The biochemical measure we recommend for monitor-
ing cortisol levels is early morning serum cortisol. This is
based on the following: (a) as discussed, this is the test
most commonly utilized to evaluate surgical success and
employing the same method ensures consistency over time,
thereby providing traceable changes, and (b) it is our
opinion that this is a convenient test as the patient needs
only to visit the clinic to have blood drawn. Alternatively,
urinary free cortisol (UFC) measurements, the most com-
monly used test for diagnosis of hypercortisolism, can also
be used. Although assessments such as ACTH levels, CRH
stimulation test, dexamethasone suppression test, and des-
mopressin stimulation test may be used, they are less
convenient: ACTH degrades quickly and sample collection
needs to be handled with great care; CRH and desmo-
pressin stimulation tests require intravenous administra-
tion, and the dexamethasone suppression test requires the
patient to take a dose of the glucocorticoid late at night and
return to the clinic the next morning to have their blood
drawn [42]. Although late-night salivary cortisol is useful
for the screening and diagnosis of patients with CD [43], it
has not been extensively studied in post-surgical patients
and is therefore not currently recommended over morning
serum cortisol [5].
Certain post-surgical treatment strategies apply to every
patient with CD, regardless of surgical outcome. It is
common for patients to experience psychiatric and physical
consequences of the disease and should receive therapeutic
care. The most common psychiatric manifestation of CD is
depression, but anxiety, mania, and psychosis also occur
[44]. Reduction of glucocorticoid action improves the
system, but patients may experience significant ‘steroid
withdrawal’ symptoms following remission despite ade-
quate glucocorticoid replacement [45]. Some patients may
have persistently reduced quality of life and impaired
cognitive function despite long-term cure [44].
Occurrence of myopathy in patients with CD is also
common and is most likely due to reduced muscle fiber
conduction and decreased levels of circulating muscle
proteins [46]. Osteoporosis is also a common feature of
prolonged hypercortisolism [20] that leads to increased risk
of bone fractures. Duration of physical and psychological
therapy will depend on individual patient needs and could
potentially lead to improvement in overall quality of life.
Immediate remission cases
Immediate remission is, by definition, a condition of acute
post-operative hypocortisolism. Accordingly, patients
whose post-operative serum levels are \2 lg/dL will
require glucocorticoid therapy. These patients should be
monitored regularly to evaluate recovery of adrenal func-
tion and exogenous glucocorticoid dose should be tapered
appropriately.
We propose that early morning serum cortisol levels of
patients in immediate remission be monitored at semian-
nual intervals for 3 years. This recommendation is based
on the finding that the highest rates of recurrence are
observed within approximately 5 years following TSS [27].
If no elevation is observed within 3 years, monitoring
frequency can be tapered to an annual basis. However,
patients should be strongly encouraged to return for testing
sooner if symptoms of CD begin to reappear at any point.
Potentially persistent cases
Patients with post-operative serum cortisol levels between
2 and 5 lg/dL require much closer monitoring. These
individuals are at increased risk for subclinical CD that is
challenging to diagnose. We recommend that the first test
be performed at 3 weeks following surgery to evaluate
changes in cortisol levels (i.e., identify cases of delayed
remission). If serum cortisol level declines to \2 lg/dL,
the patient can be considered in remission. If serum cortisol
remains elevated or if there is a mild increase in UFC
values, the patient could potentially be afflicted with sub-
clinical CD.
Careful consideration of any accompanying clinical
symptoms will determine the course of action. If symptoms
worsen over time, the first surgery was probably not
curative and a second surgery, pituitary irradiation (radio-
therapy or radiosurgery, depending on availability and the
center’s practice), or medical therapy may be considered,
as appropriate. If a mild elevation in serum cortisol or UFC
is accompanied by either no changes or by slight
improvements in clinical symptoms, the patient should be
further monitored every 2–3 months. If serum cortisol
levels then decrease to \2 lg/dL, the patient can be con-
sidered to be in remission. If not, treatment options, such as
a second surgery, pituitary irradiation, or medical therapy
may be considered if appropriate, especially if other
symptoms of CD begin to reappear.
Persistent cases
Surgery is not always curative and some patients will
remain hypercortisolemic following TSS. For patients with
post-operative serum cortisol [5 lg/dL, immediate repeat
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surgery, pituitary irradiation, or medical therapy are pos-
sible further treatment options [43, 47]. Bilateral adrenal-
ectomy (BLA) can be an alternative in some cases,
although there is a risk of the patient developing Nelson’s
syndrome; BLA also necessitates lifelong glucocorticoid
and mineralocorticoid replacement therapy.
Discussion
CD is most commonly treated by surgical removal of the
transgressing pituitary adenoma. Reported success rates
vary widely and could be a result of surgeon expertise,
reliability or timing of assays, or cut-off levels used to
define remission. Furthermore, prophylactic measures, such
as the use of pre- and/or peri-operative glucocorticoids or
steroidogenesis inhibitors may confound results from bio-
chemical assays performed soon after surgery [5]. It has
recently been suggested that peri-operative use of gluco-
corticoids may be unnecessary and that they should be
administered only if a biochemical or clinical need is
confirmed [5]. Consideration of these variables is important
because recurrence of CD following TSS is not uncommon
and the current common perception is that post-surgical
cortisol levels may predict a patient’s predisposition to
relapse.
Despite the large number of long-term follow-up studies
published, no single positive predictive factor of recurrence
has emerged. Although subnormal levels of early morning
serum cortisol levels measured within a few days following
surgery suggest a lower risk of recurrence, relapse does
occur in approximately 9 % of patients in this population
[40]. Patients who achieve normal, but not subnormal post-
surgical levels of cortisol are at a higher risk for recurrence
(*24 %), although many of these patients may experience
long-term remission [40]. Evaluation of the HPA axis in
addition to cortisol levels may provide an advantage, but
results to date are contradictory and further studies are
needed. Since there is no fail-safe predictor of recurrence,
standardized lifelong monitoring of post-surgical patients
with CD is recommended for timely detection and optimal
treatment of disease recurrence.
We propose the application of rigorous post-surgical
monitoring to patients with CD who have been treated with
TSS. Education of endocrinologists on this matter has
begun with Bertagna and Guignat’s recent publication on
the approach to the diagnosis and treatment of persistence
and recurrent CD [48]. The authors highlight the available
tests and therapeutic avenues, including combination
therapies that can be used to treat a patient not cured by
primary TSS. Based on our own clinical experiences and
understanding of the literature, we have proposed what we
believe is a feasible algorithm for post-surgical follow-up
monitoring. The algorithm represents our recommenda-
tions for post-surgical monitoring of patients with CD and
is presented with the caveat that it is designed to be a
general guide rather than a simple protocol. Treatment
decisions can be complex and must be made on a case-by-
case basis using all available information, including levels
of biochemical markers, severity of disease, the evolving
availability of medical therapies, and patient concerns and
preferences in cases of persistent hypercortisolemia.
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